Biotechs Swarm to Cure Rare AATD Liver Disease
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Beam, Wave Life Sciences, Korro Bio, Tessera, and Yoltech are all targeting alpha-1 antitrypsin deficiency (AATD), a rare disorder in which a single misspelled DNA letter causes the liver to produce a mutant protein that fails to protect the lungs.
- Analysts see a multibillion-dollar potential market, with biotechs collectively spending billions to develop cures for a disease most Americans have never heard of.
- The race features dueling technologies, patent wars, a broken alliance, and a boiling U.S.–China competition between drug industries.
- AATD was long considered a "lost cause" but has become a gold rush because new gene-editing and base-editing tools are uniquely suited to correcting the single-letter DNA error at the root of the disease.
- For patients, the disease is described as a "slow-moving disaster" as the misfolded mutant protein accumulates in and damages the liver while leaving the lungs unprotected.
Why it matters: Five named biotechs committing billions to a disease most Americans have never heard of signals that gene-editing technologies have crossed a tractability threshold — turning a once-marginal niche into a contested multibillion-dollar market where U.S. and Chinese drugmakers are now in direct competition for the same single-letter fix.
